Cennerv Pharma aims to raise US$40m for groundbreaking drugs
The biotech venture is ramping up efforts to bring to market drugs that can treat mental disorders
Add BT as a preferred source
Singapore
WHEN Anil K Ratty first endeavoured to use science to improve humankind, he had no idea of the massiveness of his task. Some 15 years later, the Singapore neuroscientist-turned-bioentrepreneur - amid developing drugs to treat mental disorders - now wants to attempt a new momentous task: to remedy the old-world risk-averse investor sentiment for biotech ventures.
Dr Ratty told BT: "One thing the market may not know of is the long runway a pharma startup requires before it can take off. The market rewards quick revenues and profits. It has still to understand and appreciate the real upside of a pharma startup, and thus focuses on the perception of the high risks associated with such enterprises. (But) throughout evolution, there is no gain without risk."
Copyright SPH Media. All rights reserved.
